Donor leukaemia: perhaps a more common occurrence than we thought!

Although allogeneic stem cell transplantation (SCT) has been a very successful treatment for many patients with haematological malignancies and bone marrow failure syndromes, relapse of the original disease remains a problem. In acute leukaemias, a number of factors appear to influence the incidence of relapse including the stage of disease at the time of SCT,1 the conditioning regimen2 and the type of graft versus host disease (GvHD) prophylaxis used.3 In patients transplanted for acute myeloid leukaemia in first remission relapse rates are very low,4 whereas patients transplanted for acute lymphoblastic leukaemia in second remission have a high rate of relapse, especially if the t(9;22) translocation is present.5 In chronic myeloid leukaemia (CML), SCT performed in first chronic phase is associated with a greater than 60% long-term disease-free survival, but relapses may occur many years after the original transplant.6 The use of T cell depletion as GvHD prophylaxis in patients undergoing SCT for CML was particularly associated with an unacceptably high rate of leukaemia relapse.7 The administration of donor lymphocytes to patients relapsing after SCT for CML is commonly associated with long-term second remissions and in some cases ‘molecular remission’ may be achieved.8 In patients with bone marrow failure syndromes, especially severe aplastic anaemia, early or late graft rejection may occur. This may be a reflection of relapse of the original disease. Rarely, autologous recovery occurs, in patients receiving SCT for leukaemia or severe aplastic anaemia.

When leukaemia relapse occurs, it is commonly assumed to be a re-emergence of the original leukaemia, however, in a number of thoroughly investigated cases, the leukaemia has been clearly demonstrated to occur in cells of donor origin.9,10,11 The incidence of ‘donor leukaemia’ is unknown because many physicians do not investigate the origin of the relapsed leukaemia cells. Rare cases of donor leukaemia occurring after bone marrow transplantation for severe aplastic anaemia have been reported.12

The mechanisms underlying ‘donor leukaemia’ remain unknown. Rare cases of occult transmission of leukaemia from the donor have been described but appear to be very uncommon.13 Putative explanations, which range from residual radiation-induced damage to stromal cells in the recipient to abnormal levels of growth factors in stromal cells in the blast crisis of CML, remain speculative. Recent radiobiological evidence of a bystander effect on nonirradiated progenitors and variations in response to radiation in different animal strains may enhance our understanding of the possible explanations for the phenomenon of ‘donor leukaemia’.

Chromosome aberrations and gene mutations induced by ionizing radiation are conventionally attributed to the DNA being irreversibly changed immediately after exposure, either during the processing and enzymatic repair of the damage or during DNA replication. However, this paradigm of genetic alterations being restricted to direct DNA damage has been challenged by the induction of mutations and chromosome aberrations in cells that are not themselves irradiated but in the neighbourhood of irradiated cells or exposed to medium in which cells have been irradiated. Such untargeted effects are collectively termed radiation-induced bystander effects.14,15 Recent investigations have revealed that genetic instability expressed in the progeny of haemopoietic stem cells can be induced by an indirect bystander-type mechanism both in vitro16 and in vivo17 in a manner consistent with an inflammatory-type mechanism involving superoxide and nitric oxide production.18,19 However, the level of induced damage is strongly influenced by genetic factors20 that may be attributed to the genotype-dependent differences in the efficiency of apoptotic response and phagocytic clearance of damaged cells in haemopoietic tissues.19 These differences may also be relevant to the genotype-dependent differences in susceptibility to radiation leukaemogenesis,21 as a more effective apoptotic response would eliminate a greater number of unstable and potentially leukaemic cells.

Prior to the recent studies of bystander effects, there are reports that superoxide radicals may induce genotoxic effects by indirect mechanisms, involving the formation of more long-lived, secondary chromosome breakage factors or clastogenic factors. These factors are present in the plasma of therapeutically or accidentally irradiated individuals, but there is considerable inter-individual variation in both production and response.22,23,24,25,26,27,28 The clastogenic factors are able to stimulate further superoxide production by competent cells and this may be the explanation for their persistence over many years. The vicious circle of formation and action shifts the pro-oxidant/anti-oxidant balance in cells towards the pro-oxidant state, and the genotoxic effects are brought about by the formation of lipid peroxidation products,29 inosine nucleotides30 and cytotoxic cytokines.31 Potentially related findings are that irradiated bone marrow stromal cells release cytokines32,33 and/or nitric oxide 34 and that the frequency of transformation of haemopoietic growth factor-dependent cells is enhanced if cocultured with irradiated bone marrow stromal cell lines35,36 or transplanted into irradiated syngeneic mice.37 There is also experimental evidence that induction of inflammatory responses in mice increases the incidence of radiation-induced acute myeloid leukaemia38 and that germ-free mice have a lower incidence of radiation-induced AML but transferring mice housed and irradiated in germ free conditions to conventional conditions increases their AML incidence.39

Overall, there is a growing body of experimental evidence that there are indirect or bystander mechanisms of radiation damage that involve oxidative stress and inflammatory-type responses to radiation-induced injury. This conclusion is consistent with the recent report of a persistent subclinical inflammation among Japanese A-bomb survivors and the suggestion that ‘radiation-induced enhancement of inflammatory reactions might contribute as an epigenetic and/or bystander effect to the development of several radiation-induced disorders’.40 While it is not yet clear how bystander effects contribute to overall cellular radiation responses in vivo, they have opened up avenues of investigation with potential relevance to understanding leukaemic relapse in donor cells.

References

  1. 1

    Bortin M, Horowitz M, Rimm, A . Increasing utilization of allogeneic bone marrow transplantation: results of the 1988–1990 survey. Ann Int Med 1992; 116: 505–512.

  2. 2

    Aurer I, Gale R . Are new conditioning regimens for transplants in acute myelogeneous leukaemia better? Bone Marrow Transplant 1991; 7: 255–611.

  3. 3

    Marmont AM, Horrowitz MM, Gale RP et al. T-cell depletion of HLA-identical transplants in leukaemia. Blood 1991; 78: 2120–2130.

  4. 4

    Frassoni F, Labopin M, Gluckman E et al. Are patients with acute leukaemia alive and well 2 years post bone marrow transplantation cured? A European survey. Acute Leukaemia Working Party of the European Group for Bone Marrow Transplantation (EMBT). Leukemia 1994; 8: 924–928.

  5. 5

    Barrett AJ, Horowtiz MM, Gale RP et al. Bone marrow transplantation for Philadelphia chromosome positive acute lymphoblastic leukemia. Blood 1992; 79: 3067–3070.

  6. 6

    Yong ASM, Goldman JM . Relapse of chronic myeloid leukaemia 14 years after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23: 827–828.

  7. 7

    Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase; increased risk of relapse associated with T-cell depletion. Ann Int Med 1988; 108: 806–814.

  8. 8

    Van Rhee F, Goldman JM . Donor lymphocyte therapy in bone marrow transplantation. In: Morstyn G., Sheridan W (eds.). Cell Therapy–Stem Cell Transplantation, Gene Therapy and Cellular Immunotherapy. Cambridge University Press: Cambridge, 1996, pp. 550–567.

  9. 9

    McCann SR, Lawler M, Bacigalupo A . Recurrence of Philadelphia chromosome-positive leukemia in donor cells after bone marrow transplantation for chronic granulocytic leukemia. Leukemia Lymphoma 1993; 10: 419–425.

  10. 10

    Lowsky R, Fyles G, Minden M et al. Detection of donor cell derived acute myelogenous leukemia in a patient transplanted for chronic myelogenous leukemia using florescence in situ hybridisation. Br J Haematol 1996; 93: 163–165.

  11. 11

    Cooley LD, Sears DA, Udden MM et al. Donor cell leukemia: report of a case occurring 11 years after allogeneic bone marrow transplantation and review of the literature. Am J Hematol 2000; 63: 46–53.

  12. 12

    Browne PV, Lawler M, Humphries P, McCann SR . Donor-cell leukemia after bone marrow transplantation for severe aplastic anemia. New Eng J 1991; 325: 710–713.

  13. 13

    Niederwiesler DW, Appelbaum FR, Gastl G et al. Inadvertent transmissions of a donor's myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia. New Engl J Med 1990; 322: 1794–1796.

  14. 14

    Grosovsky AJ . Radiation-induced mutations in unirradiated DNA. Proc Nat Acad Sci USA 1999; 96: 5346–5347.

  15. 15

    Mothersill C, Seymour C . Radiation-induced bystander effects: past history and future directions. Radiat Res 2001; 5: 759–767.

  16. 16

    Lorimore SA, Kadhim MA, Pocock DA et al. Chromosomal instability in the descendants of unirradiated surviving cells after alpha-particle irradiation. Proc Nat Acad Sci USA 1998; 5: 5730–5573.

  17. 17

    Watson GE, Lorimore SA, Macdonald DA, Wright EG . Chromosomal instability in unirradiated cells induced in vivo by a bystander effect of ionizing radiation. Cancer Res 2000; 60: 5608–5611.

  18. 18

    Clutton SM, Townsend KM, Walker C et al. Radiation-induced genomic instability and persisting oxidative stress in primary bone marrow cultures. Carcinogenesis 1996; 17: 1633–1639.

  19. 19

    Lorrimore SA, Coates PJ, Scobie GE et al. Inflammatory-type responses after exposure to ionising radiation in vivo: a mechanism for radiation-induced bystander effects? Oncogene 2001; 20: 7085–7095.

  20. 20

    Watson GE, Lorimore SA, Clutton SM et al. Genetic factors influencing alpha-particle-induced chromosomal instability. Int J Radiat Biol 1997; 71: 497–503.

  21. 21

    Wright EG . Radiation-induced genomic instability in haemopoietic cells. Int J Radiat Biol 1998; 74: 681–687.

  22. 22

    Emerit I, Levy A, Cernjavski L et al . Transferable clastogenic activity in plasma from persons exposed as salvage personnel of the Chernobyl reactor. J Cancer Res Clin Oncol 1994; 120: 558–561.

  23. 23

    Emerit I, Oganesian N, Arutyunian R et al. Oxidative stress-related clastogenic factors in plasma from Chernobyl liquidators: protective effects of antioxidant plant phenols, vitamins and oligoelements. Mutat Res 1997; 377: 239–246.

  24. 24

    Goh K, Sumner H . Breaks in normal human chromosomes: are they induced by a transferable substance in the plasma of persons exposed to total-body irradiation? Radia Res 1996; 35: 171–181.

  25. 25

    Hollowell Jr JG, Littlefield LG . Chromosome damage induced by plasma of x-rayed patients: an indirect effect of x-ray. Proc Soc Exp Biol Med 1968; 129: 240–244.

  26. 26

    Lloyd DC, Moquet JE . The clastogenic effect of irradiated human plasma. Int J Radiat Biol Relat Stud Phys Chem Med 1985; 47: 433–444.

  27. 27

    Pant GS, Kamada N . Chromosome aberrations in normal leukocytes induced by the plasma of exposed individuals. Hiroshima J Med Sci 1977; 26: 149–154.

  28. 28

    Scott D . The effect of irradiated plasma on normal human chromosomes and its relevance to the long-lived lymphocyte hypothesis. Cell Tissue Kinetics 1969; 2: 295–305.

  29. 29

    Emerit I, Khan SH, Esterbauer H . Hydroxynonenal, a component of clastogenic factors? Free Radic Biol Med 1991; 10: 371–377.

  30. 30

    Auclair C, Gouyette A, Levy A, Emerit I . Clastogenic inosinenucleotide as components of the chromosome breakage factor in scleroderma patients. Arch Biochem Biophys 1990; 278: 238–244.

  31. 31

    Emerit I, Levy A, Pagano G et al. Transferable clastogenic activity in plasma from patients with Fanconi anemia. Hum Genet 1995; 96: 14–20.

  32. 32

    Greenberger JS, Epperly MW, Jahroudi N et al. Role of bone marrow stromal cells in irradiation leukemogenesis. Acta Haematol 1996; 96: 1–15.

  33. 33

    Greenberger JS, Epperly MW, Zeevi A . Stromal cell involvement in leukemogenesis and carcinogenesis. In Vivo 1996; 10: 1–17.

  34. 34

    Gorbunov NV, Pogue-Geile KL, Epperly MW et al. Activation of the nitric oxide synthase 2 pathway in the response of bone marrow stromal cells to high doses of ionizing radiation. Radiat Res 2000; 154: 73–86.

  35. 35

    Greenberger JS, FitzGerald TJ, Klassen V et al. Alteration in hematopoietic stem cell seeding and proliferation by both high and low dose rate irradiation of bone marrow stromal cells in vitro. Int J Radiat Oncol Biol Phys 1988; 14: 85–94.

  36. 36

    Greenberger JS, Wright E, Henault S et al. Hematopoietic stem cell- and marrow stromal cell-specific requirements for gamma irradiation leukemogenesis in vitro. Exp Hematol 1990; 18: 408–415.

  37. 37

    Duhrsen U, Metcalf D . Effects of irradiation of recipient mice on the behavior and leukemogenic potential of factor-dependent hematopoietic cell lines. Blood 1990; 75: 190–197.

  38. 38

    Yoshida D, Nemoto K, Nishimura M, Seki M . Exacerbating factors of radiation-induced myeloid leukemogenesis. Leukemia Res 1993; 17: 437–440.

  39. 39

    Walburg HE, Congreve GE, Upton AC . Influence of microbial environment on development of myeloid leukemia in x-irradiated RFM mice. Int J Cancer 1968; 3: 150–154.

  40. 40

    Neriishi K, Nakashima E, Delongchamp RR . Persistent subclinical inflammation among A-bomb survivors. Int J Radiat Biol 2001; 77: 475–482.

Download references

Author information

Correspondence to S McCann.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

McCann, S., Wright, E. Donor leukaemia: perhaps a more common occurrence than we thought!. Bone Marrow Transplant 32, 455–457 (2003). https://doi.org/10.1038/sj.bmt.1704218

Download citation

Further reading